Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the FirmNEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ADMA Biologics (
NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for potential violations of the federal securities laws.
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and OlderRAMSEY, N.J. and BOCA RATON, Fla., May 04, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced the U.S. Food and Drug Administration (“FDA”) has approved the Company’s supplemental Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for ASCENIV™. The FDA approval represents the final study report for the Pediatric assessment as required in the post marketing commitment.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMANEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. (“ADMA” or the “Company”) (
NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMANEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. (“ADMA” or the “Company”) (
NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Continues – Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmGlancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (
NASDAQ: ADMA) investors concerning the Company’s possible violations of the federal securities laws.
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationLaw Offices of Howard G. Smith continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (
NASDAQ: ADMA) investors concerning the Company’s possible violations of federal securities laws.
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzThe Law Offices of Frank R. Cruz continues its investigation of ADMA Biologics, Inc. (“ADMA” or the “Company”) (
NASDAQ: ADMA) on behalf of investors concerning the Company’s possible violations of federal securities laws.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMANEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. (“ADMA” or the “Company”) (
NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ADMA Biologics (
NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for potential violations of the federal securities laws.
ADMA Fraud Notice: ADMA Biologics Investors are Notified the Company is being Investigated for Securities Fraud after 29% Stock Drop — BFA Law
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (
NASDAQ:ADMA) for potential violations of the federal securities laws.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMANEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. (“ADMA” or the “Company”) (
NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
ADMA INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ADMA Biologics, Inc.
The law firm of Kirby McInerney LLP continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (
NASDAQ:ADMA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADMA Biologics, Inc. – ADMANEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. (“ADMA” or the “Company”) (
NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
ADMA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws ViolationsNEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (
NASDAQ:ADMA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA” or the “Company”) (
NASDAQ:ADMA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
